1427 related articles for article (PubMed ID: 19249680)
1. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Pàez-Ribes M; Allen E; Hudock J; Takeda T; Okuyama H; Viñals F; Inoue M; Bergers G; Hanahan D; Casanovas O
Cancer Cell; 2009 Mar; 15(3):220-31. PubMed ID: 19249680
[TBL] [Abstract][Full Text] [Related]
2. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Loges S; Mazzone M; Hohensinner P; Carmeliet P
Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
Ebos JM; Kerbel RS
Nat Rev Clin Oncol; 2011 Mar; 8(4):210-21. PubMed ID: 21364524
[TBL] [Abstract][Full Text] [Related]
4. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Quesada AR; Medina MA; Alba E
Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
[TBL] [Abstract][Full Text] [Related]
5. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
6. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
7. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
8. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
10. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.
Ye W
Dev Cell; 2016 Apr; 37(2):114-25. PubMed ID: 27093081
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in cancer - general pathways and their therapeutic implications.
Dimova I; Popivanov G; Djonov V
J BUON; 2014; 19(1):15-21. PubMed ID: 24659637
[TBL] [Abstract][Full Text] [Related]
12. The critical role of vascular endothelial growth factor in tumor angiogenesis.
Amini A; Masoumi Moghaddam S; Morris DL; Pourgholami MH
Curr Cancer Drug Targets; 2012 Jan; 12(1):23-43. PubMed ID: 22111836
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic agents in cancer therapy.
Lenz HJ
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
[TBL] [Abstract][Full Text] [Related]
14. The great escape; the hallmarks of resistance to antiangiogenic therapy.
van Beijnum JR; Nowak-Sliwinska P; Huijbers EJ; Thijssen VL; Griffioen AW
Pharmacol Rev; 2015; 67(2):441-61. PubMed ID: 25769965
[TBL] [Abstract][Full Text] [Related]
15. VEGF in tumor progression and targeted therapy.
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Curr Cancer Drug Targets; 2013 May; 13(4):423-43. PubMed ID: 23167597
[TBL] [Abstract][Full Text] [Related]
16. Cancer: The nuances of therapy.
Ellis LM; Reardon DA
Nature; 2009 Mar; 458(7236):290-2. PubMed ID: 19295595
[No Abstract] [Full Text] [Related]
17. Antiangiogenic Activity of Acer tegmentosum Maxim Water Extract in Vitro and in Vivo.
Kim EC; Kim SH; Piao SJ; Kim TJ; Bae K; Kim HS; Hong SS; Lee BI; Nam M
J Korean Med Sci; 2015 Jul; 30(7):979-87. PubMed ID: 26130964
[TBL] [Abstract][Full Text] [Related]
18. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
19. Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits.
Moserle L; Pons R; Martínez-Lozano M; Jiménez-Valerio GA; Vidal A; Suárez C; Trilla E; Jiménez J; de Torres I; Carles J; Senserrich J; Aguilar S; Palomero L; Amadori A; Casanovas O
EMBO Mol Med; 2020 Dec; 12(12):e11889. PubMed ID: 33151035
[TBL] [Abstract][Full Text] [Related]
20. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
